Αρχική World News Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in Patients...

Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in Patients With Refractory and Relapsed Multiple Myeloma

Idecabtagene vicleucel, a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy induced responses in a majority of heavily pretreated patients with refractory and relapsed multiple myeloma. Minimal residual disease (MRD)-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 side effects, most commonly haematological side effects and cytokine release syndrome (CRS). The findings from the phase II KarMMa study are published on 25 February 2021 in The New England Journal of Medicine.

Dr. Nikhil Munshi of the Dana–Farber Cancer Institute, Harvard Medical School in Boston, MA, US and colleagues wrote in the study background that there is no standard of care for patients with multiple myeloma who have disease progression to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 antibodies. The outcomes are poor, with infrequent complete responses, a median progression-free survival (PFS) of 3 to 4 months, and a median overall survival of 8 to 9 months.

Idecabtagene vicleucel showed promising efficacy in a phase I study in patients with relapsed or refractory multiple myeloma. These results prompted a pivotal KarMMa study to assess the efficacy and safety of idecabtagene vicleucel in patients with triple-class relapsed and refractory multiple myeloma and to evaluate pharmacokinetics, immunogenicity, and potential biomarkers for response and progression.

It was an open label, single-arm, multicentre, phase II study (NCT03361748). Patients received idecabtagene vicleucel target doses of 150×106 to 450×106 CAR-positive T-cells. The primary endpoint was an overall response defined as partial response or better. A key secondary endpoint was a complete response or better, comprising complete and stringent complete responses.

Of 140 patients enrolled, 128 received idecabtagene vicleucel. At a median follow-up of 13.3 months, 94 of 128 patients (73%) had a response, and 42 of 128 (33%) had a complete response or better.

MRD–negative status was confirmed in 33 patients, representing 26% of all 128 patients who were treated and 79% of the 42 patients who had a complete response or better.

The median PFS was 8.8 months (95% confidence interval, 5.6 to 11.6).

Common side effects among the 128 treated patients included neutropenia in 117 patients (91%), anaemia in 89 (70%), and thrombocytopenia in 81 (63%). CRS was reported in 107 patients (84%), including 7 (5%) who had events of grade 3 or higher. Neurotoxic effects developed in 23 patients (18%) and were of grade 3 in 4 patients (3%). No neurotoxic effects higher than grade 3 occurred.

Cellular kinetic analysis confirmed CAR-positive T-cells in 29 of 49 patients (59%) at 6 months and 4 of 11 patients (36%) at 12 months after infusion.

The authors concluded that the results of the KarMMa study support substantial antitumour activity for idecabtagene vicleucel across a target dose range of 150×106 to 450×106 CAR-positive T-cells. The 450×106 dose appeared to be somewhat more effective than the other doses. Grade 3 or higher CRS and neurotoxic effects were observed in no more than 6% of patients at all doses of CAR-positive T-cells. High-grade haematological side effects were common but transient. Overall, a small number of adverse events were fatal.

The study was funded by bluebird bio and Celgene, a Bristol-Myers Squibb company.


Munshi NC, Anderson Jr. LD, Shah, N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 2021;384:705-16. DOI: 10.1056/NEJMoa2024850.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer

On 13 October 2021, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for...

From Scan to Scan: The Challenges of Living with Metastatic Cancer

October 15, 2021, by NCI Staff Bethany Ross has been living with metastatic neuroendocrine cancer since she was diagnosed in 2018. Credit: Used with permission from...

The award-winning researcher behind next generation sequencing

Next generation sequencing (NGS) has given the genomic research community ultra-high throughput, scalability, and speed that could only be dreamed of 20 years ago....

Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t Tell Their Doctors

Cancer and cancer treatment come with many side effects, including nausea, vomiting, and pain. In addition to the physical toll, the impacts to a...

Medicare Open Enrollment Starts Tomorrow!

Medicare open enrollment is upon us for 2022. If you are a Medicare recipient, this is the time of year when you can make...

Cancer in My Community: Providing Supportive Care in Serbia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...